Fig. 7: TACC3 deficiency increases the sensitivity of PDAC cells to chemotherapy drugs. | Cell Death & Disease

Fig. 7: TACC3 deficiency increases the sensitivity of PDAC cells to chemotherapy drugs.

From: Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer

Fig. 7

A Representative images of high/low TACC3 protein expression in PDAC samples from patients with neoadjuvant therapy. Scale bar: 100 µm. B–E Panc-1 cells was cultured with repeated gemcitabine induction to generate gemcitabine-resistant (GR) sublines. B The successful construction of gemcitabine-resistant Panc-1 sublines was verified by examining IC50 in parental cells versus GR sublines. Gene expression in gemcitabine-sensitive cell lines (WT) and GR sublines was analyzed by RNA sequencing. C Cluster heatmaps showed the relative expression levels of TACC3, KIF11 and some verified gemcitabine-resistance related genes in WT and GR sublines. D qPCR verified the differential expression of TACC3 and KIF11 in WT and GR sublines. E Western blotting validated the differential expression of TACC3 and KIF11 in WT and GR sublines. F–H Panc-1 cells were infected with scrambled shRNA (sh-Scr) or TACC3 shRNA (sh#1, sh#2) to construct stable strains. IC50 of gemcitabine (F) paclitaxel (G) and cisplatin (H) in these three group of cells was quantified. I–K Panc-1 cells were infected with scrambled shRNA (sh-Scr) or KIF11 shRNA (sh#1, sh#2) to construct stable strain. IC50 of gemcitabine (I) paclitaxel (J) and cisplatin (K) in these three group of cells was quantified. L–M To explore the combination effect of TACC3 knockdown plus chemotherapy in vivo, we constructed a mouse subcutaneous tumor model of Panc-1 cells. n = 4 biologically independent mice per group. Each group of mice were fed with PBS containing 2 μg/mL DOX to regulate the TACC3 expression (sh-Scr, shTACC3#1, shTACC3#2). Meanwhile, the combination treatment group (TACC3 + GEM) was intraperitoneally injected with 20 mg/kg gemcitabine in a PBS vehicle, and the non-combination treatment group was treated with PBS only. L Volume changes of subcutaneous tumor was monitored every 2 days and displayed by line charts. M On the 14th day of treatment, tumors were separated and photographed to show tumor size. (Unless otherwise specified, n = 3. All studies were performed with three biological replicates).

Back to article page